Susan Claster
Clinical Professor, Medicine
School of Medicine
School of Medicine
M.D., University of Chicago, 1976
University of California, Irvine
Bldg. 56 Rm. 250, Zot: 4061
Orange, CA 92628
Bldg. 56 Rm. 250, Zot: 4061
Orange, CA 92628
Research Interests
sickle cell disease
Publications
1.Claster S, Vichinsky E: First report of reversal of organ dysfunction in sickle cell anemia by the use of hydroxyurea – splenic regeneration, Blood 1996;88:1951-1953.
2.Sahud MA, Claster S, Liu L, Ero M, Harris K, Furlan M: von Willebrand factor-cleaving protease inhibitor in a patient with human immunodeficiency syndrome-associated thrombotic thrombocytopenic purpura. Br J Haematol. 2002 Mar;116(4):909-911.
3.Morris CR, Morris SM Jr, Hagar W, Van Warmerdam J, Claster S, Kepka-Lenhart D, Machado L, Kuypers FA, Vichinsky EP: Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med. 2003 Jul 1;168(1):63-69.
4.Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M: Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA, 2003, 289(13):1645-1651.
5.Ataga KI, Smith WR, DeCastro LM et al :Efficacy and Safety of the Gardos Channel Blocker,senicapoc(ICA-17043), in patients with sickle cell anemia. Blood,2008,111:3991-7.
6.Wood, J, Claster S, Carson S, Menteer JD,Hofstra T, Khanna R, Coates T: Vitamin D Deficiency, cardiac iron and cardiac function in thalassemia major. BJH, 2008,141:891-4
7.Claster S, Wood,JC,Noetzli L,Carson S, Hofstra T, Khanna R, Coates T; Nutritional Deficiencies in Iron Overloaded Patients with Hemoglobinopathies. AmJHematol.,2009,84:344-8.
8.Claster S,Termuhlen A, Schrager S, Guzman,V, Johnson C,Wolfson J, and Iverson E: Pitfalls of Using Administrative Data Sets to Describe Clinical Care in Sickle Cell Disease, Pediatric Blood and Cancer,2013 60:1936-9..
2.Sahud MA, Claster S, Liu L, Ero M, Harris K, Furlan M: von Willebrand factor-cleaving protease inhibitor in a patient with human immunodeficiency syndrome-associated thrombotic thrombocytopenic purpura. Br J Haematol. 2002 Mar;116(4):909-911.
3.Morris CR, Morris SM Jr, Hagar W, Van Warmerdam J, Claster S, Kepka-Lenhart D, Machado L, Kuypers FA, Vichinsky EP: Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med. 2003 Jul 1;168(1):63-69.
4.Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M: Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA, 2003, 289(13):1645-1651.
5.Ataga KI, Smith WR, DeCastro LM et al :Efficacy and Safety of the Gardos Channel Blocker,senicapoc(ICA-17043), in patients with sickle cell anemia. Blood,2008,111:3991-7.
6.Wood, J, Claster S, Carson S, Menteer JD,Hofstra T, Khanna R, Coates T: Vitamin D Deficiency, cardiac iron and cardiac function in thalassemia major. BJH, 2008,141:891-4
7.Claster S, Wood,JC,Noetzli L,Carson S, Hofstra T, Khanna R, Coates T; Nutritional Deficiencies in Iron Overloaded Patients with Hemoglobinopathies. AmJHematol.,2009,84:344-8.
8.Claster S,Termuhlen A, Schrager S, Guzman,V, Johnson C,Wolfson J, and Iverson E: Pitfalls of Using Administrative Data Sets to Describe Clinical Care in Sickle Cell Disease, Pediatric Blood and Cancer,2013 60:1936-9..
Graduate Programs
Hematology (IM)
Link to this profile
https://faculty.uci.edu/profile/?facultyId=6024
https://faculty.uci.edu/profile/?facultyId=6024
Last updated
01/14/2014
01/14/2014